Skip to main content
This activity is supported by an educational grant from Lilly.

Advances in Alzheimer’s

Alzheimer's research and care is changing rapidly. This clinical collection brings together the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.


Clinical evidence lacking on benefit of extended lecanemab treatment

26-03-2024 Alzheimer's Disease News

More clinical evidence is needed to guide decisions on whether to discontinue lecanemab at 18 months in patients with Alzheimer’s disease who are currently receiving it.

Full potential for anti-amyloid therapies may still to be realized

26-03-2024 Alzheimer's Disease News

Anti-amyloid treatments have transformed Alzheimer’s disease therapeutics, but more work may be needed before they are clinically useful for most patients with the disease.

Do blood-based biomarkers diagnose AD or just inform on an individual’s risk?

26-03-2024 Alzheimer's Disease News

Blood-based biomarkers are a useful tool for stratifying an individual’s risk for Alzheimer’s disease in the early stages of cognitive decline, but do they actually diagnose AD in the truest sense?

Too early for mass testing of biomarkers in patients with subjective cognitive decline

26-03-2024 Alzheimer's Disease News

Biomarkers could be useful for helping patients with subjective cognitive decline better understand the pathology associated with their symptoms, but consensus suggests that more work is needed before they are tested in every patient.

Improved amyloid clearance with donanemab vs aducanumab

12-03-2024 Alzheimer's Disease News

TRAILBLAZER-ALZ 4 trial shows greater and earlier amyloid plaque clearance at 18-months with donanemab versus aducanumab.

Success of p-tau 217 biomarker for diagnosing Alzheimer's disease

12-03-2024 Alzheimer's Disease News

Study findings support the superior biomarker potential of p-tau 217 in predicting beta-amyloid positivity and diagnosing Alzheimer’s disease.

Experts in Conversation

Alzheimer's Disease Panel Discussion

Implementing AD biomarkers and amyloid-targeting therapies

Dorota Religa and Robert Perneczky walk us through the most exciting findings from the AD/PD™ and CONy 2024 conferences.

Their discussion focuses on existing and emerging biomarkers and new amyloid-targeting therapies in Alzheimer's disease.

Highlights from CONy 2024

Sleep disturbance as a risk factor for AD

Lea Grinberg discusses sleep disturbance as a risk factor for Alzheimer’s disease in association with the accumulation of amyloid and tau proteins. 

Should lecanemab use be extended over 18 months?

Zvezdan Pirtošek comments on the debate he moderated over whether or not lecanemab should be extended beyond 18 months. 

Neurology Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy neurologist.

Highlights from AD/PD™ 2024

Research on earlier treatment with anti-amyloid immunotherapies

Oskar Hansson comments on research supporting earlier treatment with anti-amyloid monoclonal antibodies and the importance of amyloid PET imaging for monitoring patients, with the potential to treat less often.

Latest research on fluid biomarkers

Charlotte Teunissen highlights some of the research presented on AD biomarkers, including a novel assay for multiphosphorylated tau and the impact of confounding factors.


Data modeling sheds light on balancing donanemab efficacy and safety

12-03-2024 Alzheimer's Disease News

Researchers have estimated that the majority of amyloid plaque reduction achieved with donanemab treatment occurs by 64 weeks of treatment, and once off treatment, the median reaccumulation rate in patients remains low.

Disease-modifying effects of lecanemab in AD maintained through 24 months

12-03-2024 Alzheimer's Disease News

Disease-modifying effects of lecanemab continue through 24 months in patients with early Alzheimer’s disease, with those at early pathogenetic stage potentially showing the greatest benefit.

Baseline amyloid top predictor of amyloid clearance with donanemab

12-03-2024 Alzheimer's Disease News

Baseline amyloid level is a key factor for predicting amyloid plaque clearance at 24 and 52 weeks of treatment with donanemab.

Alzheimer's Disease Independent Medical Education

Keen to learn more from all the key Alzheimer's congresses? (Link opens in a new window)

Explore the full interactive education program, led by world renowned experts in Alzheimer's disease.

Supported by: Lilly

Developed by: Springer Healthcare IME

This content was originally published on Journey to a New Era for Alzheimer’s Disease, an independent education program developed by Springer Healthcare IME. This program is supported by an educational grant from Lilly. This content is intended for healthcare professionals outside of the UK.